Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX13 vs Yervoy in previously untreated unresectable advanced hepatocellular carcinoma
CTR20250866Phase 3Terminated
- Sponsor
- Henlius
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ipilimumab in hepatocellular carcinoma (HCC), sponsored by Henlius. Started Mar 2025; status: terminated.
02
Drugs
ipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20250866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250866.